Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients (NYHA Class II-IV) With Preserved Ejection Fraction (PARAGON-HF)

Trial Profile

A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients (NYHA Class II-IV) With Preserved Ejection Fraction (PARAGON-HF)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sacubitril/valsartan (Primary) ; Valsartan
  • Indications Chronic heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms PARAGON-HF
  • Sponsors Novartis; Novartis Pharma KK; Novartis Pharmaceuticals
  • Most Recent Events

    • 20 Dec 2023 Results assessing whether higher BUN/Cr is associated with worse outcomes in patients with chronic HF by deriving data from PARADIGM-HF, ATMOSPHERE & DAPA-HF and PARAGON-HF & I-PRESERVE, published in the European Journal of Heart Failure
    • 13 Nov 2023 Results assessing the association between the number of echocardiographic RVD parameters and clinical outcomes, presented at the American Heart Association Scientific Sessions 2023.
    • 13 Nov 2023 Results of cost-effectiveness analysis of sacubitril-valsartan in patients with HFmrEF/HFpEF , based on clinical event rates were based on 5-year data from the I-PRESERVE and event rates observed in the pooled analysis of the PARAGON-HF and PARAGLIDE-HF , presented at the American Heart Association Scientific Sessions 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top